Get the Stockscreener App
1.74
5.45%
0.09
After Hours:
1.72
-0.02
-1.15%
Cognition Therapeutics Inc stock is traded at $1.74, with a volume of 673.22K.
It is up +5.45% in the last 24 hours and up +9.43% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.65
Open:
$1.67
24h Volume:
673.22K
Relative Volume:
0.28
Market Cap:
$153.60M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-2.2025
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
+25.18%
1M Performance:
+9.43%
6M Performance:
+614.29%
1Y Performance:
+337.30%
1-Day Range:
$1.645
$1.765
1-Week Range:
$1.38
$1.765
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.74 | 145.65M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Cognition Therapeutics Inc Stock Analysis and ForecastConsumer Goods Stocks & Affordable Market Investment - earlytimes.in
Cognition Therapeutics Inc. (CGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Recap Report & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Cognition Therapeutics: A High-Stakes Bet On A Single DrugWhy I Hold (NASDAQ:CGTX) - Seeking Alpha
B. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
Cognition Therapeutics (CGTX) Sees Analyst Price Target Boost | - GuruFocus
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating - MarketScreener
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - The Manila Times
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Speak at Annual Piper Sandler Healthcare Conference - Quiver Quantitative
Cognition Therapeutics (Nasdaq: CGTX) CEO Talk at 37th Piper Sandler Healthcare Conf - Stock Titan
Will Cognition Therapeutics Inc. stock beat EPS estimatesJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Can Cognition Therapeutics Inc. stock beat analyst upgradesEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
What analyst consensus says on Cognition Therapeutics Inc. stock - newser.com
Will Cognition Therapeutics Inc. stock pay special dividendsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
HC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
How to use a screener to detect Cognition Therapeutics Inc. breakoutsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Cognition Therapeutics Inc. stock appeals to dividend seekersIndex Update & Long-Term Growth Plans - newser.com
Analyzing Cognition Therapeutics Inc. with multi timeframe charts2025 Biggest Moves & Fast Moving Market Watchlists - newser.com
James M. O’Brien Appointed Chief Financial Officer at Mesoblast - GlobeNewswire Inc.
Cognition Therapeutics Announces $30.1M Direct Offering - MSN
Relative strength of Cognition Therapeutics Inc. in sector analysis2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Will earnings trigger a reversal in Cognition Therapeutics Inc.July 2025 Technicals & Real-Time Volume Triggers - newser.com
Will Cognition Therapeutics Inc. stock benefit from upcoming earnings reports2025 Historical Comparison & Reliable Price Breakout Signals - newser.com
Smart tools for monitoring Cognition Therapeutics Inc.’s price actionTrade Ideas & Risk Controlled Swing Trade Alerts - newser.com
Is Cognition Therapeutics Inc. stock cheap at current valuationJuly 2025 Technicals & AI Driven Price Forecasts - newser.com
Will Cognition Therapeutics Inc. stock benefit from commodity pricesTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com
Why Cognition Therapeutics Inc. stock is a value investor pick2025 Bull vs Bear & Expert-Curated Trade Recommendations - newser.com
Published on: 2025-11-14 10:43:14 - Fundação Cultural do Pará
Cognition Therapeutics completes enrollment in Alzheimer’s drug trial By Investing.com - Investing.com Canada
Strategies to average down on Cognition Therapeutics Inc.July 2025 Breakouts & Verified Entry Point Signals - newser.com
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine in Early Alzheimer's Disease - MarketScreener
Cognition Therapeutics completes enrollment in Alzheimer’s drug trial - Investing.com
Cognition Therapeutics Announces Successful Enrollment in Phase 2 'START' Study for Zervimesine in Alzheimer’s Disease - Quiver Quantitative
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - The Manila Times
Cognition (NASDAQ: CGTX) completes Phase 2 enrollment at 540; 15% on Leqembi or Kisunla - Stock Titan
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):